NCT02041234View on ClinicalTrials.gov

Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

December 31, 2020

Study Completion Date

June 30, 2022

Conditions
Type II Diabetes in Subjects BMI 27 to 32
Interventions
PROCEDURE

Roux-en-Y Gastric Bypass (RYGB)

Roux-en-Y Gastric Bypass (RYGB) as per standard surgical protocol, with a 30 cc gastric pouch, 50 cm biliopancreatic limb and 100cm gastrointestinal limb.

DRUG

Incretin analogues

Incretin analogues: Liraglutide up to 1.8 mg daily

DRUG

Xenical

Xenical: Up to 120 mg tds

DRUG

SGLT2 inhibitors

SGLT2 inhibitors: Empagliflozin up to 25mg daily, Canagliflozin up to 300mg daily

DRUG

DPP-4 Inhibitors

Sitagliptin up to 100 mg daily, Linagliptin up to 5mg daily

Trial Locations (1)

768828

Khoo Teck Puat Hospital, Singapore

All Listed Sponsors
lead

Khoo Teck Puat Hospital

OTHER

NCT02041234 - Roux-en-Y Gastric Bypass for BMI 27-32 Type 2 Diabetes Versus Best Medical Treatment | Biotech Hunter | Biotech Hunter